GLP-1 Market
LLY $1143.12 ▲ +0.0% NVO $37.54 ▲ +0.6% PFE $27.41 ▼ -1.4% VKTX $29.28 ▼ -2.2% KLRA $10.84 ▲ +4.3% GPCR $27.59 ▼ -0.3% RHHBY $52.51 ▲ +0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Chiglitazar , dose 2

Company
Chipscreen Biosciences, Ltd.
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 5, 2026

Trial details
  • Completed NCT NCT07519265

    Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets

    Not yet reported Chipscreen Biosciences, Ltd. 64 participants Est. completion 2026-08-03 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Chiglitazar , dose 2, Chiglitazar tablet, dose 2

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.